A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

This study compares rocbrutinib, a new targeted drug, against existing BTK inhibitor drugs (a standard type of treatment) in patients with relapsed or treatment-resistant mantle cell lymphoma — a type of blood cancer. **You may be eligible if...** - You have been diagnosed with mantle cell lymphoma - You have received at least one prior treatment and your disease has progressed - You have at least one measurable lesion on imaging - Your general health status is adequate (ECOG 0–2) - Your life expectancy is at least 12 weeks - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You are allergic to rocbrutinib or to the comparator drugs in the study - You have previously received any BTK-targeted therapy (unless you had to stop due to intolerance) - Your lymphoma has spread to the brain or spinal cord - You have had another cancer within the past 2 years (with limited exceptions) - You have had major heart events in the past 6 months - You have uncontrolled infections or serious systemic illnesses Talk to your doctor to see if this trial is right for you.